MTOR and Hyperglycemia: Moreover, severe effects are associated with the inhibition of (mammalian target of rapamycin) (mTOR)-regulated pathways, such as immunosuppression, dyslipidemia, and hyperglycemia due to nonspecific biodistribution after the oral administration of Rapa [5,6].